Loading…
Spok Holdings, Inc., through its subsidiary, Spok, Inc., engages in the healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. Its products and services enhance workflows for clinicians and support administrative compliance. The company delivers clinical information to care teams when and where it matters to enhance patient outcomes; and provides GenA Pager, a one-way alphanumeric pager. It offers subscriptions to one-way or two-way messaging services, as well as alphanumeric pagers that are configurable to support unencrypted or encrypted operation; and ancillary services, such as voicemail, and equipment loss or maintenance protection services, as well as sells devices to resellers who lease or resell them to their subscribers. The company provides Spok Care Connect suite products for contact centers, clinical alerting and notification, mobile communications and messaging, and public safety notifications. In addition, it provides professional, software license updates, and product support services, as well as sells third-party equipment. It serves businesses, professionals, management personnel, medical personnel, field sales personnel and service forces, members of the construction industry and construction trades, real estate brokers and developers, sales and services organizations, specialty trade organizations, manufacturing organizations, and government agencies. The company was formerly known as USA Mobility, Inc. and changed its name to Spok Holdings, Inc. in July 2014. Spok Holdings, Inc. was founded in 1986 and is headquartered in Plano, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $140M | $24M | $16M | $25M | 10.8% | 1.5% | 6.1% |
| 2024 | $138M | $24M | $15M | $26M | 9.7% | -1.0% | -4.5% |
| 2023 | $139M | $26M | $16M | $23M | 9.6% | 3.3% | -28.3% |
| 2022 | $135M | $11M | $22M | $3M | 12.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 134.53 | 139.03 | 137.65 | 139.71 |
| Cost Of Revenue | 28.27 | 27.09 | 28.71 | 29.79 |
| Gross Profit | 106.27 | 111.93 | 108.95 | 109.92 |
| Operating Expense | 98.70 | 90.13 | 88.88 | 89.75 |
| Operating Income | 7.57 | 21.80 | 20.07 | 20.17 |
| EBITDA | 11.14 | 26.30 | 24.22 | 23.60 |
| EBIT | 7.57 | 21.80 | 20.07 | 20.17 |
| Pretax Income | 1 | 22.32 | 20.03 | 21.44 |
| Tax Provision | -20.86 | 6.66 | 5.07 | 5.56 |
| Net Income | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income Common Stockholders | 21.86 | 15.67 | 14.96 | 15.88 |
| Total Expenses | 126.97 | 117.22 | 117.58 | 119.54 |
| Interest Income | 0.59 | 1.10 | 1.15 | 0.82 |
| Research And Development | 13.62 | 10.68 | 11.69 | 12.22 |
| Selling General And Administration | 54.09 | 47.80 | 47.40 | 49.51 |
| Normalized EBITDA | 18.47 | 26.87 | 25.32 | 24.05 |
| Normalized Income | 27.65 | 16.07 | 15.79 | 16.22 |
| Basic EPS | 1.11 | 0.79 | 0.74 | 0.77 |
| Diluted EPS | 1.09 | 0.77 | 0.73 | 0.75 |
| Tax Effect Of Unusual Items | -1.54 | -0.17 | -0.28 | -0.12 |
| Tax Rate For Calcs | 0.21 | 0.30 | 0.25 | 0.26 |
| Total Unusual Items | -7.33 | -0.57 | -1.10 | -0.46 |
| Total Unusual Items Excluding Goodwill | -7.33 | -0.57 | -1.10 | -0.46 |
| Net Income From Continuing Operation Net Minority Interest | 21.86 | 15.67 | 14.96 | 15.88 |
| Reconciled Depreciation | 3.57 | 3.84 | 3.45 | 3.34 |
| Reconciled Cost Of Revenue | 28.27 | 27.75 | 29.40 | 29.88 |
| Net Interest Income | 0.59 | 1.10 | 1.15 | 0.82 |
| Net Income From Continuing And Discontinued Operation | 21.86 | 15.67 | 14.96 | 15.88 |
| Rent Expense Supplemental | 21.26 | 18.76 | 0 | 0 |
| Total Operating Income As Reported | 0.24 | 21.23 | 18.96 | 19.71 |
| Diluted Average Shares | 19.99 | 20.34 | 20.57 | 21.05 |
| Basic Average Shares | 19.67 | 19.95 | 20.24 | 20.55 |
| Diluted NI Availto Com Stockholders | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income Including Noncontrolling Interests | 21.86 | 15.67 | 14.96 | 15.88 |
| Net Income Continuous Operations | 21.86 | 15.67 | 14.96 | 15.88 |
| Other Income Expense | -7.16 | -0.57 | -1.19 | 0.45 |
| Other Non Operating Income Expenses | 0.17 | 0 | -0.09 | 0.91 |
| Special Income Charges | -7.33 | -0.57 | -1.10 | -0.46 |
| Write Off | 0.75 | 0.33 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | 7.33 | 0.57 | 1.10 | 0.46 |
| Net Non Operating Interest Income Expense | 0.59 | 1.10 | 1.15 | 0.82 |
| Interest Income Non Operating | 0.59 | 1.10 | 1.15 | 0.82 |
| Other Operating Expenses | 27.41 | 27.14 | 25.64 | 24.60 |
| Other Taxes | 1.01 | 1.03 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 3.57 | 4.50 | 4.15 | 3.43 |
| Depreciation And Amortization In Income Statement | 3.57 | 4.50 | 4.15 | 3.43 |
| Amortization | 0 | 0 | 0 | 0 |
| Amortization Of Intangibles Income Statement | 0 | 0 | 0 | 0 |
| Depreciation Income Statement | 2.89 | 4.50 | 4.15 | 3.43 |
| Selling And Marketing Expense | 16.30 | 16.75 | 16.22 | 17.70 |
| General And Administrative Expense | 37.80 | 31.06 | 31.18 | 31.80 |
| Other Gand A | 37.80 | 31.06 | 31.18 | 31.80 |
| Rent And Landing Fees | 21.26 | 18.76 | 0 | 0 |
| Salaries And Wages | 38.76 | 36.43 | 0 | 0 |
| Operating Revenue | 134.53 | 139.03 | 137.65 | 139.71 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Spok Holdings, Inc.this co. | SPOK | $229M | 14.73↑ premium | 1.56 | 10.8% | 8.93 |
| 908 Devices Inc. | MASS | $243M | - | 1.64 | 13.6% | -6.49 |
| Carlsmed, Inc. | CARL | $240M | - | 2.38 | -30.0% | -4.74 |
| Arcturus Therapeutics Holdings Inc. | ARCT | $239M | - | 1.12 | -30.7% | -0.45 |
| Nuvectis Pharma, Inc. | NVCT | $235M |
| - |
| 11.85 |
| -143.6% |
| - |
| Heron Therapeutics, Inc. | HRTX | $224M | - | 16.76 | -140.9% | -1425.96 |
| Voyager Therapeutics, Inc. | VYGR | $220M | - | 1.10 | -61.1% | -0.46 |
| Keros Therapeutics, Inc. | KROS | $220M | 4.83 | 0.72 | 28.7% | -0.72 |
| Sight Sciences, Inc. | SGHT | $216M | - | 3.32 | -60.1% | -4.83 |
| Peer Median | - | 4.83 | 2.01 | -45.4% | -4.74 | |